Convert Pharmaceuticals is a pioneering platform company specializing in the development of prodrugs that remain inert until they reach the tumor site. These innovative drugs then transform into powerful anti-cancer agents within the tumor microenvironment. Leveraging proprietary insights into tumor biology and specific biomarkers, Convert Pharmaceuticals meticulously designs prodrugs to specifically target tumor hypoxia, a major contributor to cancer treatment resistance.
Tumor hypoxia is a common characteristic found in approximately 50% of solid tumors. Through our cutting-edge development of two key biomarkers, we have discovered that certain cancer types are particularly responsive to our therapies. These include pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, and head and neck squamous cell carcinoma, positioning our treatments at the forefront of combating these challenging diseases.
CP-506, Convert’s hypoxia-activated prodrug, shows no dose-limiting toxicity and confirms tumour-selective activation in the Phase I TUMAGNOSTIC trial....
Convert Pharmaceuticals’ EIC Accelerator project, TUMAGNOSTIC, formally concluded at the end of December 2025. Supported by the European Innovation Council, the project enabled Convert to advance its lead clinical candidate, CP-506, from preclinical development into clinical evaluation. CP-506 is a hypoxia-activated prodrug designed to selectively......
In this news, we would like to break down how hypoxia fuels cancer, why past attempts to target it failed, and how we’re working to turn hypoxia into a weapon against itself. Part 1: Tumor Hypoxia – The “Stealth Mode” of Cancer Tumor hypoxia refers......